Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
Tóm tắt
Từ khóa
Tài liệu tham khảo
Archin, 2012, Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy, Nature, 487, 482, 10.1038/nature11286
Banerjee, 2012, BET bromodomain inhibition as a novel strategy for reactivation of HIV-1, J. Leukoc. Biol., 92, 1147, 10.1189/jlb.0312165
Bar-On, 2018, Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals, Nat. Med., 24, 1701, 10.1038/s41591-018-0186-4
Battivelli, 2018, Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells, eLife, 7, e34655, 10.7554/eLife.34655
Bauer, 1999, Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, Science, 285, 727, 10.1126/science.285.5428.727
Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol. Ther. Oncolytics, 3, 16011, 10.1038/mto.2016.11
Borducchi, 2018, Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys, Nature, 563, 360, 10.1038/s41586-018-0600-6
Bruel, 2016, Elimination of HIV-1-infected cells by broadly neutralizing antibodies, Nat. Commun., 7, 10844, 10.1038/ncomms10844
Cameron, 2010, Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton, Proc. Natl. Acad. Sci. USA, 107, 16934, 10.1073/pnas.1002894107
Caskey, 2017, Antibody 10-1074 suppresses viremia in HIV-1-infected individuals, Nat. Med., 23, 185, 10.1038/nm.4268
Caskey, 2019, Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic, Nat. Med., 25, 547, 10.1038/s41591-019-0412-8
Cavrois, 2017, Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells, Cell Rep., 20, 984, 10.1016/j.celrep.2017.06.087
Cella, 2010, Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection, Eur. J. Immunol., 40, 949, 10.1002/eji.200940234
Chun, 1995, In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency, Nat. Med., 1, 1284, 10.1038/nm1295-1284
Chun, 1997, Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy, Proc. Natl. Acad. Sci. USA, 94, 13193, 10.1073/pnas.94.24.13193
Chun, 1999, Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy, Nat. Med., 5, 651, 10.1038/9498
Chun, 2008, Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy, J. Infect. Dis., 197, 714, 10.1086/527324
Cillo, 2014, Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy, Proc. Natl. Acad. Sci. USA, 111, 7078, 10.1073/pnas.1402873111
Cohn, 2018, Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation, Nat. Med., 24, 604, 10.1038/s41591-018-0017-7
Cosman, 2001, ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor, Immunity, 14, 123, 10.1016/S1074-7613(01)00095-4
Deeks, 2002, A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy, Mol. Ther., 5, 788, 10.1006/mthe.2002.0611
Deng, 2015, Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations, Nature, 517, 381, 10.1038/nature14053
Doitsh, 2010, Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue, Cell, 143, 789, 10.1016/j.cell.2010.11.001
Eroshkin, 2014, bNAber: database of broadly neutralizing HIV antibodies, Nucleic Acids Res., 42, D1133, 10.1093/nar/gkt1083
Fedorov, 2013, PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses, Sci. Transl. Med., 5, 215ra172, 10.1126/scitranslmed.3006597
Finzi, 1997, Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, 278, 1295, 10.1126/science.278.5341.1295
Goulder, 2018, HIV control: Is getting there the same as staying there?, PLoS Pathog., 14, e1007222, 10.1371/journal.ppat.1007222
Graham, 2018, Allogeneic CAR-T Cells: More than Ease of Access?, Cells, 7, E155, 10.3390/cells7100155
Guedan, 2018, Engineering and Design of Chimeric Antigen Receptors, Mol. Ther. Methods Clin. Dev., 12, 145, 10.1016/j.omtm.2018.12.009
Haase, 1996, Quantitative image analysis of HIV-1 infection in lymphoid tissue, Science, 274, 985, 10.1126/science.274.5289.985
Hale, 2017, Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells, Mol. Ther., 25, 570, 10.1016/j.ymthe.2016.12.023
Herbst, 2002, IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer, Semin. Oncol., 29, 18, 10.1016/S0093-7754(02)70087-0
Hersperger, 2010, Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control, PLoS Pathog., 6, e1000917, 10.1371/journal.ppat.1000917
Hocqueloux, 2010, Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection, AIDS, 24, 1598, 10.1097/QAD.0b013e32833b61ba
Hunt, 2003, T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy, J. Infect. Dis., 187, 1534, 10.1086/374786
Jacobson, 2019, CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma, J. Clin. Oncol., 37, 328, 10.1200/JCO.18.01457
Jain, 2013, Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size, J. Infect. Dis., 208, 1202, 10.1093/infdis/jit311
Jean, 2019, Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors, AIDS Res. Hum. Retroviruses, 35, 1, 10.1089/aid.2018.0153
Jiang, 2018, HIV latency is reversed by ACSS2-driven histone crotonylation, J. Clin. Invest., 128, 1190, 10.1172/JCI98071
Jones, 2016, HIV-specific CD8+ T cells and HIV eradication, J. Clin. Invest., 126, 455, 10.1172/JCI80566
Julg, 2019, Neutralizing antibodies for HIV-1 prevention, Curr. Opin. HIV AIDS, 14, 318, 10.1097/COH.0000000000000556
Kalams, 1999, Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy, J. Virol., 73, 6721, 10.1128/JVI.73.8.6721-6728.1999
Ke, 2018, Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design, JCI Insight, 3, 123052, 10.1172/jci.insight.123052
Keele, 2008, Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection, Proc. Natl. Acad. Sci. USA, 105, 7552, 10.1073/pnas.0802203105
Kharsany, 2016, HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities, Open AIDS J., 10, 34, 10.2174/1874613601610010034
Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388
Kutsch, 2002, Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency, J. Virol., 76, 8776, 10.1128/JVI.76.17.8776-8786.2002
Laird, 2015, Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations, J. Clin. Invest., 125, 1901, 10.1172/JCI80142
Landgraf, 2019, convertibleCAR-T cells provide a modular universal system for dose control of activity, flexible targeting, and versatile maintenance of CAR-cells, bioRxiv
Leonard, 1988, Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection, Proc. Natl. Acad. Sci. USA, 85, 3570, 10.1073/pnas.85.10.3570
Levy, 2004, Dynamics of HIV-1 recombination in its natural target cells, Proc. Natl. Acad. Sci. USA, 101, 4204, 10.1073/pnas.0306764101
Li, 2019, Variable infectivity and conserved engagement in cell-to-cell viral transfer by HIV-1 Env from Clade B transmitted founder clones, Virology, 526, 189, 10.1016/j.virol.2018.10.016
Li, 2013, The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation, Nucleic Acids Res., 41, 277, 10.1093/nar/gks976
Li, 2016, The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption, AIDS, 30, 343
Lori, 1999, Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir, J. Infect. Dis., 180, 1827, 10.1086/315113
Ma, 2019, Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch, Stem Cell Rev Rep, 15, 443, 10.1007/s12015-019-09876-5
Malbec, 2013, Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission, J. Exp. Med., 210, 2813, 10.1084/jem.20131244
Maloney, 1997, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma, Blood, 90, 2188, 10.1182/blood.V90.6.2188
Manson McManamy, 2014, Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors, Antivir. Chem. Chemother., 23, 145, 10.3851/IMP2551
Matusali, 2013, Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells, FASEB J., 27, 2440, 10.1096/fj.12-223057
Mayer, 2017, Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial, PLoS Med., 14, e1002435, 10.1371/journal.pmed.1002435
McCoy, 2018, The expanding array of HIV broadly neutralizing antibodies, Retrovirology, 15, 70, 10.1186/s12977-018-0453-y
McGill, 2010, IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection, J. Exp. Med., 207, 521, 10.1084/jem.20091711
Mehla, 2010, Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner, PLoS ONE, 5, e11160, 10.1371/journal.pone.0011160
Migueles, 2008, Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control, Immunity, 29, 1009, 10.1016/j.immuni.2008.10.010
Mouquet, 2012, Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies, Proc. Natl. Acad. Sci. USA, 109, E3268, 10.1073/pnas.1217207109
Muñoz-Arias, 2015, Blood-Derived CD4 T Cells Naturally Resist Pyroptosis during Abortive HIV-1 Infection, Cell Host Microbe, 18, 463, 10.1016/j.chom.2015.09.010
Neidleman, 2017, Mucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells, PLoS Pathog., 13, e1006163, 10.1371/journal.ppat.1006163
Onea, 2016, CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphomas, Am. J. Cancer Res., 6, 403
Osborn, 2016, Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases, Mol. Ther., 24, 570, 10.1038/mt.2015.197
Pache, 2015, BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency, Cell Host Microbe, 18, 345, 10.1016/j.chom.2015.08.009
Pantaleo, 1993, HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease, Nature, 362, 355, 10.1038/362355a0
Parrish, 2013, Phenotypic properties of transmitted founder HIV-1, Proc. Natl. Acad. Sci. USA, 110, 6626, 10.1073/pnas.1304288110
Prins, 1999, Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy, AIDS, 13, 2405, 10.1097/00002030-199912030-00012
Rasmussen, 2016, Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?, Curr. Opin. HIV AIDS, 11, 394, 10.1097/COH.0000000000000279
Rasmussen, 2013, Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials, Hum. Vaccin. Immunother., 9, 790, 10.4161/hv.23202
Ren, 2017, Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition, Clin. Cancer Res., 23, 2255, 10.1158/1078-0432.CCR-16-1300
Renju, 2017, ‘Side effects’ are ‘central effects’ that challenge retention in HIV treatment programmes in six sub-Saharan African countries: a multicountry qualitative study, Sex. Transm. Infect., 93, e052971, 10.1136/sextrans-2016-052971
Richer, 2015, Inflammatory IL-15 is required for optimal memory T cell responses, J. Clin. Invest., 125, 3477, 10.1172/JCI81261
Richman, 2009, The challenge of finding a cure for HIV infection, Science, 323, 1304, 10.1126/science.1165706
Roybal, 2016, Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011
Ruella, 2017, Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf, BioDrugs, 31, 473, 10.1007/s40259-017-0247-0
Sáez-Cirión, 2013, Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study, PLoS Pathog., 9, e1003211, 10.1371/journal.ppat.1003211
Sampey, 2018, The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent, bioRxiv
Samri, 2016, Polyfunctional HIV-specific T cells in Post-Treatment Controllers, AIDS, 30, 2299, 10.1097/QAD.0000000000001195
Sarkar, 2018, Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, J. Natl. Cancer Inst.
Scheid, 2011, Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding, Science, 333, 1633, 10.1126/science.1207227
Scheid, 2016, HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption, Nature, 535, 556, 10.1038/nature18929
Scholler, 2012, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci. Transl. Med., 4, 132ra53, 10.1126/scitranslmed.3003761
Schuitemaker, 1992, Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population, J. Virol., 66, 1354, 10.1128/jvi.66.3.1354-1360.1992
Schuitemaker, 2011, Clinical significance of HIV-1 coreceptor usage, J. Transl. Med., 9, S5, 10.1186/1479-5876-9-S1-S5
Schwartz, 2018, Characterization of the Plasmacytoid Dendritic Cell Response to Transmitted/Founder and Nontransmitted Variants of HIV-1, J. Virol., 92, 10.1128/JVI.00157-18
Shacklett, 2019, Tissue issues: mucosal T-cell responses in HIV-1 infection, Curr. Opin. HIV AIDS, 14, 100, 10.1097/COH.0000000000000530
Shan, 2012, Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation, Immunity, 36, 491, 10.1016/j.immuni.2012.01.014
Shan, 2013, A novel PCR assay for quantification of HIV-1 RNA, J. Virol., 87, 6521, 10.1128/JVI.00006-13
Shields, 2001, High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem., 276, 6591, 10.1074/jbc.M009483200
Shin, 2007, CD8 T cell dysfunction during chronic viral infection, Curr. Opin. Immunol., 19, 408, 10.1016/j.coi.2007.06.004
Siliciano, 2011, HIV latency, Cold Spring Harb. Perspect. Med., 1, a007096, 10.1101/cshperspect.a007096
Sok, 2016, A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans, Immunity, 45, 31, 10.1016/j.immuni.2016.06.026
Sotillo, 2015, Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy, Cancer Discov., 5, 1282, 10.1158/2159-8290.CD-15-1020
Steinle, 2001, Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family, Immunogenetics, 53, 279, 10.1007/s002510100325
Sung, 2018, HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals, Mol. Ther., 26, 2496, 10.1016/j.ymthe.2018.08.015
Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019
Themeli, 2013, Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy, Nat. Biotechnol., 31, 928, 10.1038/nbt.2678
Torikai, 2016, Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors, Mol. Ther., 24, 1178, 10.1038/mt.2016.106
Tsai, 2017, Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy, J. Virol., 91, e02166-16, 10.1128/JVI.02166-16
Vaidya, 2017, A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor, Pharmacology, 100, 229, 10.1159/000478663
Wagner, 2018, Quarter Century of Anti-HIV CAR T Cells, Curr. HIV/AIDS Rep., 15, 147, 10.1007/s11904-018-0388-x
Walker, 2011, Broad neutralization coverage of HIV by multiple highly potent antibodies, Nature, 477, 466, 10.1038/nature10373
Walker, 2017, Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase, Mol. Ther., 25, 2189, 10.1016/j.ymthe.2017.06.008
Walker-Sperling, 2016, The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication, EBioMedicine, 8, 217, 10.1016/j.ebiom.2016.04.019
Wang, 2016, Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015, Lancet HIV, 3, e361, 10.1016/S2352-3018(16)30087-X
Watanabe, 2015, Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells, J. Immunol., 194, 911, 10.4049/jimmunol.1402346
Wong, 1997, Recovery of replication-competent HIV despite prolonged suppression of plasma viremia, Science, 278, 1291, 10.1126/science.278.5341.1291
Xu, 2019, Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility, Cell Stem Cell, 24, 566, 10.1016/j.stem.2019.02.005
Yang, 2002, Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes, J. Virol., 76, 1626, 10.1128/JVI.76.4.1626-1631.2002
Yang, 2015, Challenges and opportunities of allogeneic donor-derived CAR T cells, Curr. Opin. Hematol., 22, 509, 10.1097/MOH.0000000000000181
Younes, 2016, IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection, J. Clin. Invest., 126, 2745, 10.1172/JCI85996
Yukl, 2010, Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy, J. Infect. Dis., 202, 1553, 10.1086/656722
Zhen, 2017, Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS, PLoS Pathog., 13, e1006753, 10.1371/journal.ppat.1006753